Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 1996
Industry: Medical technology, manufacturing, and diagnostics
Key Financial Metrics
| Metric | Q1 1996 | Q1 1995 |
|---|---|---|
| Revenues | $655.8 million | $639.9 million |
| Net Income | $58.1 million | $44.5 million |
| Earnings Per Share (EPS) | $0.44 | $0.32 |
| Operating Income | $86.5 million | $71.9 million |
| Gross Profit Margin | 47.7% | 45.5% |
| Operating Margin | 13.2% | 11.2% |
| Cash from Operations | $139.0 million | $88.8 million |
| Short-Term Debt | $161.5 million | $227.4 million (Sep 1996) |
| Long-Term Debt | $468.2 million | $468.2 million (Sep 1996) |
| Cash and Equivalents | $152.7 million | $135.2 million (Sep 1996) |
Material Changes vs. Prior Period
- Revenue Growth: Reported revenue increased 3% year-over-year. Adjusted for a stronger dollar (-$11 million) and divested businesses (-$27 million), organic growth was approximately 9%.
- Profitability: Net income rose 31% and EPS increased 38%, driven by a 20% increase in operating income and share repurchases.
- Margins: Gross profit margin improved by 2.2 percentage points due to a more profitable product mix and productivity gains. Operating margin expanded from 11.2% to 13.2%.
- Segment Performance:
- Medical Supplies & Devices: Revenues slightly higher; adjusted growth ~11%.
- Diagnostic Systems: Revenues up 5% (7% adjusted for currency).
- Domestic Medical: Revenues down 2% reported; up ~9% adjusted for divestitures.
- International Medical: Revenues up 3% reported; up 12% adjusted.
- Cash Flow: Operating cash flow increased significantly to $139 million, aided by improved net income and lower working capital requirements.
Guidance, Outlook, and Management Commentary
- Capital Expenditures: Q1 capex was $31 million. Full-year capex is expected to be slightly higher than the prior year's $146 million.
- Debt Management: Issued $100 million in 6.90% Notes (due 2006) to repay commercial paper. Debt-to-capitalization ratio improved to 31.9% from 36.5% a year ago. Entered a new $500 million five-year revolving credit facility.
- Shareholder Returns:
- Repurchased 1.1 million shares for $45 million; 13.7 million shares remain authorized for repurchase.
- Quarterly dividend increased from $0.115 to $0.13 per share.
- Unusual Items: Other income included a $4 million gain from the sale of the infusion pump business.
- Accounting Change: Effective January 1, 1997, Mexican operations will be treated as operating in a highly inflationary economy, moving translation gains/losses to net income. Management does not expect a material impact.
Investor Verification Checklist
- Verify the impact of the stronger U.S. dollar on future international revenue projections.
- Confirm the sustainability of the 2.2 percentage point gross margin improvement.
- Monitor the execution of the $13.7 million remaining share repurchase authorization.
- Assess the potential volatility in net income resulting from the new accounting treatment for Mexican operations (highly inflationary economy).
- Review the performance of the Diagnostic Systems segment given the noted impact of U.S. cost containment initiatives.